Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 2
2015 1
2016 6
2017 9
2018 15
2019 28
2020 25
2021 32
2022 28
2023 14
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 34620731

120 results

Results by year

Filters applied: . Clear all
Page 1
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.
Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohamad O, Pampaloni MH, Scott PJH, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Piert M. Ferdinandus J, et al. J Nucl Med. 2022 Jan;63(1):76-80. doi: 10.2967/jnumed.121.262821. Epub 2021 Oct 7. J Nucl Med. 2022. PMID: 34620731 Free PMC article.
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
Roberts MJ, Chatfield MD, Hruby G, Nandurkar R, Roach P, Watts JA, Cusick T, Kneebone A, Eade T, Ho B, Nguyen A, Tang C, McCarthy M, Francis R, Stricker P, Emmett L. Roberts MJ, et al. BJU Int. 2022 Nov;130 Suppl 3(Suppl 3):32-39. doi: 10.1111/bju.15762. Epub 2022 Jul 12. BJU Int. 2022. PMID: 35488182 Free PMC article.
Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.
Ke ZB, Chen SM, Chen JY, Chen SH, You Q, Sun JB, Xue YT, Sun XL, Wu XH, Zheng QS, Wei Y, Xue XY, Xu N. Ke ZB, et al. Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1240-1251. doi: 10.1007/s00259-022-06047-6. Epub 2022 Nov 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 36416906
Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, Sedelaar JPM, Küsters-Vandevelde HVN, Gotthardt M, Wijers CHW, van Basten JP, Somford DM. Baas DJH, et al. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):65-70. doi: 10.1038/s41391-021-00452-y. Epub 2021 Sep 1. Prostate Cancer Prostatic Dis. 2022. PMID: 34471231
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. Calais J, et al. Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Lancet Oncol. 2019. PMID: 31375469 Free PMC article. Clinical Trial.
120 results